George Kumar Shares Breakthrough in Cold Plasma Oncology
George Kumar, Senior Director at AstraZeneca, shared a post on LinkedIn about a paper by Lea Miebach et al. published on Cancer Cell:
“Redefining Cold Plasma Oncology: Short-Lived ROS, Not Hydrogen Peroxide, Drive Deep-Tissue Anticancer Effects
Gas plasma technology mediates deep tissue and anticancer events independently of hydrogen peroxide
Lea Miebach et al. (Trends in Biotechnology, 2025) have revealed that short-lived reactive species, not hydrogen peroxide, are the true effectors of cold plasma’s anticancer action—penetrating deep into tissue to kill tumor cells, even after surgery. This insight opens new doors to more precise, effective, and potentially relapse-mitigating cancer treatments.
Additional Observations
- Surgical Context: Applying the kINPen plasma jet to simulated surgical resection sites led to the elimination of residual tumor cells, suggesting potential to reduce post-surgery relapse.
- Mechanistic Implication: These results highlight the critical role of short‑lived reactive species rather than H₂O₂, offering key mechanistic insights for optimizing plasma devices in oncological therapies.
Figure Courtesy: Leibniz-Institut für Plasmaforschung und Technologie e.V.”
Title: Gas plasma technology mediates deep tissue and anticancer events independently of hydrogen peroxide
Authors: Lea Miebach, Marten Hagge, Alice Martinet, Debora Singer, Nadine Gelbrich, Stephan Kersting, Sander Bekeschus
Read the full article.
More posts featuring George Kumar on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023